Outcome of Board Meeting dated 18th May 2026.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Chemkart India Ltd, a BSE SME-listed nutraceutical trading and distribution company, declared audited standalone and consolidated financial results for H2 and FY2025-26. Statutory auditors M/s Bagaria & Co. LLP issued an un-modified opinion on the financials. Consolidated revenue grew to Rs. 21,482.91 lakh from Rs. 20,327.85 lakh (5.7% YoY growth), with H2 standalone PAT of Rs. 1,010.20 lakh. The company completed its IPO in July 2025 raising Rs. 6,448 lakh, which significantly strengthened net worth to Rs. 12,972.98 lakh from Rs. 5,328.22 lakh. Total assets increased to Rs. 15,671.06 lakh. The board also appointed new internal and secretarial auditors. Key auditor emphasis was placed on pending customs litigation where Rs. 1,474.26 lakh has been paid as recoverable with no provision made.
Solid financial performance with strong balance sheet post-IPO. However, negative operating cash flow of Rs. 272.53 lakh (consolidated) and the undisclosed customs litigation risk of Rs. 1,474.26 lakh require monitoring. The emphasis of matter from auditors signals potential contingent liability.